Toronto Dominion Bank trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,247,683 shares of the biopharmaceutical company’s stock after selling 149,022 shares during the period. Toronto Dominion Bank owned 0.10% of Gilead Sciences worth $84,276,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Advisors Preferred LLC bought a new stake in Gilead Sciences during the 2nd quarter valued at about $26,000. Trustcore Financial Services LLC purchased a new stake in shares of Gilead Sciences during the first quarter valued at approximately $34,000. Weaver Consulting Group bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $34,000. Legacy Advisors LLC purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $37,000. Finally, Evolution Wealth Advisors LLC purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $46,000. 79.89% of the stock is owned by hedge funds and other institutional investors.

In other news, EVP Brett A. Pletcher sold 608 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $64.35, for a total value of $39,124.80. Following the transaction, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Olsen Per Wold sold 4,908 shares of Gilead Sciences stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $63.91, for a total value of $313,670.28. Following the transaction, the director now directly owns 102,762 shares in the company, valued at $6,567,519.42. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,532 shares of company stock valued at $1,221,149. Insiders own 0.20% of the company’s stock.

Several brokerages have commented on GILD. ValuEngine downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. Jefferies Financial Group set a $95.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, July 15th. Raymond James set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Friday, August 23rd. BidaskClub cut Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Finally, Wells Fargo & Co upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $68.00 to $88.00 in a report on Monday, July 15th. Three analysts have rated the stock with a sell rating, five have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $82.24.

Shares of NASDAQ:GILD traded up $0.42 during trading on Wednesday, hitting $67.50. The company’s stock had a trading volume of 2,523,692 shares, compared to its average volume of 5,460,585. The company has a 50-day moving average of $64.48 and a 200-day moving average of $65.43. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.76 and a quick ratio of 3.67. The firm has a market cap of $84.00 billion, a price-to-earnings ratio of 10.97, a P/E/G ratio of 3.15 and a beta of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.54 billion. During the same period in the previous year, the business posted $1.91 earnings per share. The firm’s quarterly revenue was down 2.8% compared to the same quarter last year. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 6.66 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.73%. The ex-dividend date is Thursday, September 12th. Gilead Sciences’s dividend payout ratio is presently 40.98%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: What is a trade deficit?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.